Advertisement
BDX vs CNMD
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. CONMED Corporation (CNMD) Stock Comparison
Key Takeaways
- Becton, Dickinson (BDX) is a large-cap medical technology leader now repositioned as a pure-play MedTech company after separating its biosciences and diagnostics business.
- CONMED (CNMD) is a smaller, surgical-focused medtech firm refocusing its portfolio on three core platforms: AirSeal, Buffalo Filter, and BioBrace.
- BDX offers scale, diversification, and a dividend, while CNMD offers higher-margin growth platforms but carries elevated leverage and smaller liquidity.
- Both companies have been shaped by tariff, China, and portfolio-restructuring themes in recent quarters, though their market positioning differs sharply.
- Relative performance favors BDX on stability and trend consistency, while CNMD presents a higher-beta, catalyst-driven profile.
Introduction
Medical technology investors often weigh established, diversified franchises against smaller, more focused operators with faster growth potential. This stock comparison examines BDX (Becton, Dickinson and Company) and CNMD (CONMED Corporation), two healthcare names at very different stages of their corporate lifecycles. BDX is a global leader repositioning itself as a pure-play MedTech company following a major business separation, while CNMD is a surgical-device specialist streamlining its portfolio around a handful of high-growth products. Understanding how these two businesses diverge in scale, growth drivers, balance-sheet strength, and market sentiment can help both long-term investors and short-term traders assess their relative market positioning.
BDX Overview and Recent Performance
BDX is one of the world's largest medical technology companies, spanning medication delivery, connected care, and interventional products. In recent quarters, management has emphasized the "New BD" strategy centered on the priorities of compete, innovate, and deliver, following the completed separation of its biosciences and diagnostic solutions business. Recent market activity reflects a blend of operational strength and focused headwinds. In its most recent quarterly results, BDX reported revenue growth near the mid-single-digit range on an FX-neutral (foreign-exchange-adjusted) basis, with adjusted operating margins around 24% and growth led by biologic drug delivery, advanced patient monitoring, and PureWick. Sentiment has also been shaped by a substantial multi-year U.S. manufacturing investment commitment tied to tariff considerations, alongside known pressures from Alaris, vaccines, and China market dynamics. The company continues to return significant capital to shareholders through buybacks and dividends.
CNMD Overview and Recent Performance
CNMD is a surgical-focused medical technology company providing devices used primarily in orthopedic and general surgery. In recent quarters, management has pursued a portfolio-optimization strategy that includes exiting its gastroenterology (GI) product lines to concentrate resources on three key growth platforms: AirSeal (a minimally invasive access system), Buffalo Filter (surgical smoke evacuation), and BioBrace (a soft-tissue reinforcement implant). Recent performance has been supported by organic constant-currency sales growth in the mid-single digits and expanding adjusted gross margins, with adjusted earnings per share (EPS) rising meaningfully year over year. International demand has been a bright spot, while domestic reported sales have been tempered by the GI exits. The company has also refreshed its leadership, appointing a new chief financial officer (CFO) and adding board members, while refinancing a portion of its debt.
Trending AI Robots
For traders who prefer a data-driven approach to navigating names like these, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of securities. Because not every bot suits every market environment, only the best and most appropriate performers for current conditions earn a place in the Trending AI Robots section. The robots vary widely in their statistics, holding periods, and risk profiles, allowing traders to compare approaches before committing capital. Explore the Trending AI Robots page to review the latest featured strategies and their historical performance.
Head-to-Head Comparison
The most striking contrast between these two names is scale and diversification. BDX is a large-cap operator with a consumables-heavy portfolio generating predictable recurring revenue, a long-standing dividend, and broad geographic reach. CNMD is a smaller company with a concentrated product set and a heavier reliance on capital-equipment and single-use attach rates tied to surgical procedure volumes. Growth drivers also differ: BDX leans on biologic drug delivery, pharmacy automation, and monitoring consumables, while CNMD depends on the adoption curve of AirSeal in robotic and laparoscopic surgery, smoke-evacuation legislation, and BioBrace expansion. On risk, BDX faces execution risk around its business separation and China exposure, whereas CNMD carries higher leverage relative to operating cash flow and sensitivity to procedure-volume fluctuations. Market sentiment toward BDX reflects a debate over valuation and timing, while CNMD's narrative centers on whether its refocused portfolio can convert product momentum into steadier earnings and free cash flow.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalyst durability, Tickeron's AI would likely favor BDX in the current environment. The company's scale, recurring-revenue mix, dividend support, and broader diversification provide a more stable and persistent trend profile than the smaller, higher-beta setup at CNMD. While CNMD offers potentially faster growth and improving margins, its elevated leverage, narrower product base, and reliance on procedure-volume catalysts introduce greater variability. This assessment is probabilistic rather than definitive: relative positioning could shift if CNMD's growth platforms accelerate or if BDX encounters setbacks in its post-separation execution. Traders and investors should weigh these dynamics against their own objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a Hold and CNMD is a Buy.
BDX's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for BDX moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In 19 of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
BDX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BDX as a result. In 57 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for BDX just turned positive on October 09, 2026. Looking at past instances where BDX's MACD turned positive, the stock continued to rise in 27 of 48 cases over the following month. The odds of a continued upward trend are 56%.
BDX moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BDX crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +3.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDX advanced for three days, in 133 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 45%.
The Aroon Indicator entered an Uptrend today. In 111 of 219 cases where BDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. BDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.128) is normal, around the industry mean (4.887). P/E Ratio (57.452) is within average values for comparable stocks, (35.995). Projected Growth (PEG Ratio) (1.107) is also within normal values, averaging (4.456). BDX has a moderately high Dividend Yield (0.022) as compared to the industry average of (0.006). P/S Ratio (2.290) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
CNMD's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CNMD turned positive on October 15, 2026. Looking at past instances where CNMD's MACD turned positive, the stock continued to rise in 35 of 47 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CNMD's RSI Indicator exited the oversold zone, 24 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 57%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 67 cases where CNMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
Following a +2.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNMD advanced for three days, in 202 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CNMD as a result. In 72 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
CNMD moved below its 50-day moving average on September 17, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CNMD crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for CNMD entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. CNMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.324) is normal, around the industry mean (2.908). P/E Ratio (24.892) is within average values for comparable stocks, (2.616). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.052). Dividend Yield (0.017) settles around the average of (0.009) among similar stocks. P/S Ratio (1.055) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
BDX | CNMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 88 | 100 | |
SMR RATING 1..100 | 85 | 81 | |
PRICE GROWTH RATING 1..100 | 50 | 45 | |
P/E GROWTH RATING 1..100 | 7 | 5 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CNMD's Valuation (61) in the Medical Specialties industry is in the same range as BDX (71). This means that CNMD’s stock grew similarly to BDX’s over the last 12 months.
BDX's Profit vs Risk Rating (88) in the Medical Specialties industry is in the same range as CNMD (100). This means that BDX’s stock grew similarly to CNMD’s over the last 12 months.
CNMD's SMR Rating (81) in the Medical Specialties industry is in the same range as BDX (85). This means that CNMD’s stock grew similarly to BDX’s over the last 12 months.
CNMD's Price Growth Rating (45) in the Medical Specialties industry is in the same range as BDX (50). This means that CNMD’s stock grew similarly to BDX’s over the last 12 months.
CNMD's P/E Growth Rating (5) in the Medical Specialties industry is in the same range as BDX (7). This means that CNMD’s stock grew similarly to BDX’s over the last 12 months.
| BDX | CNMD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 57% |
| Stochastic ODDS (%) | 2 days ago 47% | 2 days ago 69% |
| Momentum ODDS (%) | 2 days ago 55% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 49% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 52% | 2 days ago 77% |
| Advances ODDS (%) | 6 days ago 45% | 8 days ago 68% |
| Declines ODDS (%) | 2 days ago 42% | 2 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 56% | N/A |
| Aroon ODDS (%) | 2 days ago 51% | 2 days ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 1 FA rating(s) are green while CNMD’s FA Score has 1 green FA rating(s).
- BDX’s FA Score: 1 green, 4 red.
- CNMD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 6 TA indicator(s) are bullish while CNMD’s TA Score has 4 bullish TA indicator(s).
- BDX’s TA Score: 6 bullish, 4 bearish.
- CNMD’s TA Score: 4 bullish, 5 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +3.43% price change this week, while CNMD (@Medical/Nursing Services) price change was +4.46% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.77%. For the same industry, the average monthly price growth was -2.59%, and the average quarterly price growth was +7.55%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.88%. For the same industry, the average monthly price growth was -9.59%, and the average quarterly price growth was -10.00%.
Reported Earning Dates
BDX is expected to report earnings on Nov 05, 2026.
CNMD is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.77% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-2.88% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +1.60% | ||
| COO - BDX | 55% Loosely correlated | +1.65% | ||
| TMO - BDX | 50% Loosely correlated | +1.18% | ||
| BAX - BDX | 50% Loosely correlated | -1.92% | ||
| CNMD - BDX | 48% Loosely correlated | +3.32% | ||
| MMSI - BDX | 48% Loosely correlated | +1.36% | ||
More | ||||
CNMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, CNMD has been loosely correlated with NVST. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CNMD jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To CNMD | 1D Price Change % | ||
|---|---|---|---|---|
| CNMD | 100% | +3.32% | ||
| NVST - CNMD | 49% Loosely correlated | +1.59% | ||
| KIDS - CNMD | 49% Loosely correlated | +6.67% | ||
| IART - CNMD | 48% Loosely correlated | -0.89% | ||
| ENOV - CNMD | 47% Loosely correlated | +4.13% | ||
| ZBH - CNMD | 46% Loosely correlated | +1.06% | ||
More | ||||